transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Continuous Administration of a P450 Aromatase Inhibitor Induces Polycystic Ovary Syndrome with a Metabolic and Endocrine Phenotype in Female Rats at Adult Age

Författare och institution:
Manuel Maliqueo (Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi); M. Sun (-); Julia Johansson (Institutionen för neurovetenskap och fysiologi); Anna Benrick (Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi); F. Labrie (-); Henrik Svensson (Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin); Malin Lönn (Institutionen för biomedicin, avdelningen för klinisk kemi och transfusionsmedicin); A. J. Duleba (-); Elisabet Stener-Victorin (Institutionen för neurovetenskap och fysiologi, sektionen för fysiologi)
Publicerad i:
Endocrinology, 154 ( 1 ) s. 434-445
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Studying the mechanisms for the complex pathogenesis of polycystic ovary syndrome (PCOS) requires animal models with endocrine, reproductive, and metabolic features of the syndrome. Hyperandrogenism seems to be a central factor in PCOS, leading to anovulation and insulin resistance. In female rats, continuous administration of letrozole, a nonsteroidal inhibitor of P450 aromatase, at 400 mu g/d starting before puberty induces hyperandrogenemia and reproductive abnormalities similar to those in women with PCOS. However, despite high circulating testosterone levels, these rats do not develop metabolic abnormalities, perhaps because of their supraphysiological testosterone concentrations or because estrogen synthesis is completely blocked in insulin-sensitive tissues. To test the hypothesis that continuous administration of lower doses of letrozole starting before puberty would result in both metabolic and reproductive phenotypes of PCOS, we performed a 12-wk dose-response study. At 21 d of age, 46 female Wistar rats were divided into two letrozole groups (100 or 200 mu g/d) and a control group (placebo). Both letrozole doses resulted in increased body weight, inguinal fat accumulation, anovulation, larger ovaries with follicular atresia and multiples cysts, endogenous hyperandrogemia, and lower estrogen levels. Moreover, rats that received 200 mu g/d had insulin resistance and enlarged adipocytes in inguinal and mesenteric fat depots, increased circulating levels of LH, decreased levels of FSH, and increased ovarian expression of Cyp17a1 mRNA. Thus, continuous administration of letrozole, 200 mu g/d, to female rats for 90 d starting before puberty results in a PCOS model with reproductive and metabolic features of the syndrome. (Endocrinology 154: 434-445, 2013)
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin
Postens nummer:
Posten skapad:
2013-02-08 14:02

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007